Anti-CD38/CD3 T cell-redirecting bispecific antibody (Sorrento Therapeutics)

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameAnti-CD38/CD3 T cell-redirecting bispecific antibody (Sorrento Therapeutics)
Drug Alias Nameanti-CD38/CD3 bispecific antibody (Sorrento Therapeutics)anti-CD3/anti-CD38 bispecific T-cell engager (Sorrento Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD38CD3 T-cell engagers
TargetsLymphocyte differentiation antigen CD38T cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSorrento Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSorrento Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A